Adjunct Professor of Plastic and Reconstructive Surgery, Cleveland Clinic & Executive Vice President of Medical Affairs, Iovance Biotherapeutics
Plastic and Reconstructive Surgery - Cleveland Clinic
Cleveland, OH, United States
Brian Gastman, MD is the current Executive Vice President of Medical Affairs at Iovance Biotherapeutics and Adjunct Professor of Plastic and Reconstructive Surgery at Cleveland Clinic. Dr. Gastman is a double boarded Plastic Surgeon and Otolaryngologist at Cleveland Clinic. He earned his medical degree from the University of Michigan then completed residencies in Otolaryngology and Plastic Surgery at the University of Pittsburgh, and fellowship training in head and neck and micro-surgery at Washington University in St. Louis. Dr. Gastman is the former Co-Medical and Surgical Director of Cleveland Clinic and Taussig Cancer Center’s melanoma and high-risk skin cancer program. In that role, he led the melanoma clinical trials program and multiple tumor boards, as well as building care paths and overseeing multiple quality metrics that impacted patient care and survival. Moreover, he was critical in establishing TIL therapy at the Cleveland Clinic, building the nexus of medical and surgical oncologists along with cell therapy physicians. A prominent thought leader in his field, Dr. Gastman founded and currently leads the Society of Immunotherapy of Cancer (SITC)’s Surgery Committee. He was also a member of the National Comprehensive Cancer Network (NCCN) melanoma and the non-melanoma skin cancer committees for many years. In 2022, he was Chair of the Plastic Surgery Research Council, the second oldest plastic surgery society, hosting the annual international meeting in Cleveland, Ohio. He is also highly involved with the NCI-based Cancer Immunotherapy Trial’s Network (CITN), ECOG and SWOG. Dr. Gastman also serves as an associate editor for numerous journal publications, including the Journal of ImmunoTherapy of Cancer.
Sunday, September 29, 2024
4:42 PM – 4:48 PM EDT
Disclosure information not submitted.